Welcome to our dedicated page for Senti Biosciences Holdings news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences Holdings stock.
Senti Biosciences Holdings, Inc. (SNTI) operates through Senti Bio as a clinical-stage biotechnology company developing cell and gene therapies built on a proprietary Gene Circuit synthetic biology platform. The company’s Gene Circuits are designed to program cells to sense, compute and respond to cellular environments, with applications intended to kill cancer cells, spare healthy cells, improve tissue specificity and allow post-administration control.
Recurring SNTI news centers on the Logic-Gated SENTI-202 program, an off-the-shelf CAR NK cell therapy targeting CD33 and/or FLT3 while sparing EMCN-expressing healthy cells in relapsed or refractory acute myeloid leukemia. Company updates also cover clinical and translational data presentations, peer-reviewed research on NOT-gated CAR circuits in T cells and NK cells, FDA designations for SENTI-202, financial results, conference appearances, and partnership discussions tied to the Gene Circuit platform.
Senti Biosciences (Nasdaq: SNTI) will present in person at BioJapan October 8-10, 2025. The presentation by Timothy Lu, MD, PhD, CEO and co-founder, is scheduled for Thursday, October 9 at 11:30 AM JST on Presentation Stage C at PACIFICO Yokohama Convention Center in Yokohama, Japan.
Management will be available for one-on-one investor meetings with qualified registered attendees and will host an exhibition booth at D-53. For participation details, refer to the conference website.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, will participate in the upcoming MedInvest Biotech & Pharma Conference in Palo Alto, California.
Dr. Kanya Rajangam, President, Head of Research & Development and Chief Medical Officer, will deliver a presentation on Wednesday, September 24, 2025, at 9:55 AM PT. The management team will also be available for one-on-one meetings with qualified investors attending the conference.
A live webcast of the presentation will be accessible through the Events page in the Investors section of sentibio.com.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
Co-Founder and CEO Dr. Timothy Lu will deliver a presentation on September 8, 2025, at 2:00 PM ET in New York. The company's management will also be available for one-on-one meetings with qualified investors attending the conference. A live webcast of the presentation will be accessible through Senti Bio's website and archived for 90 days.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies through its Gene Circuit platform, has announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.
The virtual presentation will be delivered by Timothy Lu, M.D., Ph.D., the company's Co-Founder and Chief Executive Officer, on Tuesday, August 19, 2025, at 2:20 PM ET. The event is part of a broader virtual conference running from August 19-21, 2025.
Senti Biosciences (NASDAQ:SNTI) participated in a Virtual Investor segment to discuss the Phase 2 dose selection for SENTI-202, their Logic Gated off-the-shelf CAR-NK cell therapy. The presentation was led by Dr. Kanya Rajangam, President, Head of R&D and Chief Medical Officer.
SENTI-202 is being developed as a potential first-in-class treatment for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The discussion focused on the recently announced recommended Phase 2 dosing schedule for the clinical trial.
Senti Biosciences (NASDAQ:SNTI), a clinical-stage biotech company, has reported its Q2 2025 financial results and provided key updates on its SENTI-202 program for Acute Myeloid Leukemia (AML). The company has completed the dose-finding phase and confirmed the recommended Phase 2 dose (RP2D) in its ongoing Phase 1 clinical trial. SENTI-202 received FDA Orphan Drug Designation for AML treatment.
Financial highlights include cash position of $21.6M as of June 30, 2025 (down from $48.3M in December 2024), R&D expenses of $10.0M (up $0.8M YoY), and G&A expenses of $6.8M (up $2.6M YoY). The company reported a net loss of $14.7M ($0.56 per share) for Q2 2025. Additionally, Senti Bio secured a $1.0M grant from CIRM for SENTI-202's clinical development.
Senti Biosciences (Nasdaq: SNTI) has determined the recommended Phase 2 dose (RP2D) for its Phase 1 study of SENTI-202, a first-in-class Logic Gated CAR-NK cell therapy for treating relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).
The RP2D was established at 1.5 x 109 CAR+ NK cells/dose, administered on Days 0, 7, and 14 of 28-Day Cycles. Early efficacy data shows promising results with 2 of 3 patients achieving composite Complete Remission (cCR) in the preliminary RP2D cohort, and 5 of 7 evaluable patients achieving Overall Response Rate (ORR). All complete remission patients (4 of 4) were MRD-negative, with durability extending to 8+ months.
The company expects to report topline data from the expansion cohort before year-end 2025. SENTI-202 has received FDA Orphan Drug Designation.
Senti Biosciences (NASDAQ:SNTI), a clinical-stage biotechnology company, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. The company's Co-Founder and CEO, Dr. Timothy Lu, presented at the event, sharing insights about his journey, dedication to the company, and passion for their development programs.
The presentation, which focuses on Senti's proprietary Gene Circuit platform for next-generation cell and gene therapies, is now available for viewing on virtualinvestorco.com and the company's investor relations website.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company, announced that its Chief Medical Officer, Dr. Kanya Rajangam, will deliver a presentation at the BioScience Forum on July 23, 2025 in San Carlos, CA.
The presentation, titled "Using Logic Gated CARs to Drive Cancer Treatment," will showcase Senti Bio's innovative logic-gated CAR-NK cell therapy technology, which is designed to target leukemic cells while preserving healthy bone marrow. The BioScience Forum serves the Bay Area biotechnology community by featuring discussions on cutting-edge discoveries in therapeutic areas including oncology and infectious diseases.
Senti Biosciences (Nasdaq: SNTI), a clinical-stage biotechnology company developing Gene Circuit-based cell and gene therapies, has appointed Bryan Baum to its Board of Directors. Baum, Co-Founder and Managing Partner of K5 Global, brings extensive entrepreneurial and investment experience with investments in major companies like SpaceX, OpenAI, and Uber.
As a serial entrepreneur, Baum has founded and successfully sold multiple companies, including Parrot (sold to Filevine), Blue Vision Labs (sold to Lyft), and Represent.com (sold to CustomInk). His expertise in scaling successful companies and strategic insights will support Senti Bio's development of Logic Gated cell therapies for cancer treatment.